Earnings digests and industry comparisons for Japan's biggest listed companies.
3 reports
OTC and Skin Care Medicines companies diverged in FY2026 interim results: Kobayashi sales rose, but operating profit fell 67.5%. Rohto's Q1 sales and operating profit grew 11.8% and 16.8%, respectively; the reporting periods differ.
Core growth widened the profit gap.
Mid-Tier Drugmakers and Drug Discovery Firms in Q1 FY2027 split between sales growth and earnings gains. Nippon Shinyaku's revenue rose 24.1%, while Ono's operating profit climbed 39.4% despite lower sales; Peptide Dream remained loss-making.
Growth leaders and profit leaders were different companies.
Japan's Big Pharma posted average sales growth of 7.7% in FY2026, with eight of nine companies expanding. Margins ranged from Chugai's 47.6% to Eisai's 5.3%, as earnings reflected both drug growth and one-off gains.
Sales growth and earnings quality separated the winners from the laggards.
